PHBID (Neorich Biopharma Tech Co) PS Ratio: 112.50 (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neorich Biopharma Tech Co PS Ratio?

Neorich Biopharma Tech Co PHBID -10.00% PS Ratio is 112.50 as of Aug. 16, 2026.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Neorich Biopharma Tech Co's share price is $0.90. Neorich Biopharma Tech Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01. Hence, Neorich Biopharma Tech Co's PS Ratio for today is 112.50.

The historical rank and industry rank for Neorich Biopharma Tech Co's PS Ratio or its related term are showing as below:

PHBID's PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.31
* Ranked among companies with meaningful PS Ratio only.

Neorich Biopharma Tech Co's Revenue per Sharefor the three months ended in Jun. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01.

Back to Basics: PS Ratio


Neorich Biopharma Tech Co  (OTCPK:PHBID) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Neorich Biopharma Tech Co PS Ratio Related Terms


Neorich Biopharma Tech Co PS Ratio Historical Data

* Premium members only.

The historical data trend for Neorich Biopharma Tech Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neorich Biopharma Tech Co PS Ratio Chart

Neorich Biopharma Tech Co Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neorich Biopharma Tech Co Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PHBID vs DVLP, CSTF, BLMS: PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neorich Biopharma Tech Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neorich Biopharma Tech Co PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neorich Biopharma Tech Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where Neorich Biopharma Tech Co's PS Ratio falls into.



Neorich Biopharma Tech Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Neorich Biopharma Tech Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.90/0.008
=112.50

Neorich Biopharma Tech Co's Share Price of today is $0.90.
Neorich Biopharma Tech Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 112.50 mean?
Neorich Biopharma Tech Co (PHBID) has a PS Ratio of 112.50 as of Aug. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Neorich Biopharma Tech Co and its competitors.
Is Neorich Biopharma Tech Co's PS Ratio too high?
Neorich Biopharma Tech Co's current PS Ratio is 112.50. The Drug Manufacturers industry median PS Ratio is 2.31. Neorich Biopharma Tech Co's value of 112.50 is 4770.1% above this industry median.
How does Neorich Biopharma Tech Co's PS Ratio compare to DVLP and CSTF?
Neorich Biopharma Tech Co's PS Ratio of 112.50 can be compared against companies in the Drug Manufacturers industry. The industry median PS Ratio is 2.31. Neorich Biopharma Tech Co's value of 112.50 is 4770.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neorich Biopharma Tech Co's current PS Ratio of 112.50 is 4770.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Neorich Biopharma Tech Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neorich Biopharma Tech Co's current PS Ratio is 112.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neorich Biopharma Tech Co stock overvalued right now?
Neorich Biopharma Tech Co (PHBID) has a current PS Ratio of 112.50. The current PS Ratio is 112.50 and 4770.1% above the Drug Manufacturers industry median of 2.31. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Neorich Biopharma Tech Co (PHBID), the current PS Ratio is 112.50 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neorich Biopharma Tech Co Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.